APP and early-onset autosomal dominant Alzheimer disease: In addition, Ishida et al. reported that chronic administration of CGA attenuated cognitive impairments and prevented Aβ deposition and neuronal loss in APP/PS2 transgenic mouse model of Alzheimer's disease (Ishida et al., 2020).